The future of human gene therapy.

[1]  M. Cipolla.  Pathophysiology and clinical applications of nitric oxide , 2000 .

[2]  R. Samulski,et al.  Roles of Adeno-Associated Virus Rep Protein and Human Chromosome 19 in Site-Specific Recombination , 2000, Journal of Virology.

[3]  V. Krasnykh,et al.  Genetic targeting of adenoviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[5]  M. Brenner.  Reports of adenovector "death" are greatly exaggerated. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[7]  J. Isner,et al.  Stem cell therapy and gene transfer for regeneration , 2000, Gene Therapy.

[8]  P. Herrling,et al.  Progress and potential for gene-based medicines. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. Giaccia,et al.  Development of a hypoxia-responsive vector for tumor-specific gene therapy , 2000, Gene Therapy.

[10]  B. Carter.  Gene therapy as drug development. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  M. Lusky,et al.  Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. , 2000, Human gene therapy.

[12]  L. Phillips,et al.  Glucose regulated production of human insulin in rat hepatocytes , 2000, Gene Therapy.

[13]  P. Boekstegers,et al.  Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins , 2000, Gene Therapy.

[14]  S. Ylä-Herttuala,et al.  Cardiovascular gene therapy , 2000, The Lancet.

[15]  J. Pearlman,et al.  Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.

[16]  J. Polak,et al.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial , 1999, The Lancet.

[17]  Sally Lehrman,et al.  Virus treatment questioned after gene therapy death , 1999, Nature.

[18]  W. Hancock,et al.  Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[19]  J. Isner,et al.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. , 1999, The Annals of thoracic surgery.

[20]  M. Post,et al.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.

[21]  M. Balter.  Support Builds for Allègre's Reforms , 1999, Science.

[22]  I. Chen,et al.  Lentiviral Vectors--the Promise of Gene Therapy Within Reach? , 1999, Science.

[23]  A. Asai,et al.  Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. , 1999, Cancer research.

[24]  S. Kochanek,et al.  Frequency and Stability of Chromosomal Integration of Adenovirus Vectors , 1999, Journal of Virology.

[25]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[26]  D. Cumberland,et al.  Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. , 1999, Circulation.

[27]  A. Thor,et al.  Systemic Gene Delivery Expands the Repertoire of Effective Antiangiogenic Agents* , 1999, The Journal of Biological Chemistry.

[28]  P. Kuppen,et al.  Specific tumor-cell killing with adenovirus vectors containing the apoptin gene , 1999, Gene Therapy.

[29]  M. Bureau,et al.  High-efficiency gene transfer into skeletal muscle mediated by electric pulses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[31]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[32]  G. Palù,et al.  Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans , 1999, Gene Therapy.

[33]  E. Svensson,et al.  Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. , 1999, Circulation.

[34]  M. Marcelli,et al.  Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. , 1999, Cancer research.

[35]  P. Musiani,et al.  Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. , 1999, Cancer research.

[36]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[38]  J. Isner,et al.  Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. , 1998, Circulation.

[39]  H. Blau,et al.  VEGF gene delivery to muscle: potential role for vasculogenesis in adults. , 1998, Molecular cell.

[40]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Munford,et al.  Physiologically responsive gene therapy. , 1998, Molecular medicine today.

[42]  T. Liu,et al.  Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  K. Channon.  Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications , 1998 .

[44]  N. Lemoine,et al.  Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis , 1998, Gene Therapy.

[45]  P. Opolon,et al.  Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice , 1998, Gene Therapy.

[46]  Simon C Watkins,et al.  Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. , 1998, Circulation.

[47]  M. Aoki,et al.  Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene , 1998, Gene Therapy.

[48]  J D Pearlman,et al.  Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. , 1998, The Annals of thoracic surgery.

[49]  L. Ellis,et al.  Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.

[50]  J. Isner,et al.  Mouse model of angiogenesis. , 1998, The American journal of pathology.

[51]  K Walsh,et al.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.

[52]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[53]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.

[54]  B. V. von Specht,et al.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.

[55]  E. Nabel,et al.  Expression of cyclin-dependent kinase inhibitors in vascular disease. , 1998, Circulation research.

[56]  K. March,et al.  Gene therapy for restenosis: getting nearer the heart of the matter. , 1998, Circulation research.

[57]  D. Dichek,et al.  Gene therapy for restenosis: are we ready? , 1998, Circulation research.

[58]  Y. Kaneda,et al.  Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. , 1998, Circulation research.

[59]  T. Libermann,et al.  Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  W. Schaper,et al.  The delivery of angiogenic factors to the heart by microsphere therapy , 1998, Nature Biotechnology.

[61]  Jennifer L Hall,et al.  Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease , 1998, Nature Medicine.

[62]  R. Vile,et al.  Strategies for achieving multiple layers of selectivity in gene therapy. , 1998, Molecular medicine today.

[63]  E. Chau,et al.  Large Unruptured Aneurysm in Sinus of Valsalva , 1998 .

[64]  I. Zachary,et al.  Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.

[65]  A. Melcher,et al.  Personal paper: Gene therapy for cancer—managing expectations , 1997, BMJ.

[66]  Shannon R. Magari,et al.  Pharmacologic control of a humanized gene therapy system implanted into nude mice. , 1997, The Journal of clinical investigation.

[67]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[68]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[69]  T. Clackson.  Controlling mammalian gene expression with small molecules. , 1997, Current opinion in chemical biology.

[70]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[71]  R. Crystal,et al.  Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. , 1997, Circulation.

[72]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[73]  S. Ylä-Herttuala.  Vascular gene transfer. , 1997, Current opinion in lipidology.

[74]  H. Matsuzaki,et al.  Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. , 1997, Blood.

[75]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[76]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.

[77]  S. Morrison,et al.  Design and production of novel tetravalent bispecific antibodies , 1997, Nature Biotechnology.

[78]  A. Belldegrun,et al.  Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. , 1997, Cancer research.

[79]  J. Isner,et al.  Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. , 1996, Circulation.

[80]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[81]  D. Curiel,et al.  Targeted gene delivery by tropism-modified adenoviral vectors , 1996, Nature Biotechnology.

[82]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[83]  G. Karsenty,et al.  Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. , 1996, Cancer research.

[84]  E. Nabel,et al.  A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. , 1996, Human gene therapy.

[85]  Shannon R. Magari,et al.  A humanized system for pharmacologic control of gene expression , 1996, Nature Medicine.

[86]  S. Schreiber,et al.  Dimeric ligands define a role for transcriptional activation domains in reinitiation , 1996, Nature.

[87]  Takayuki Asahara,et al.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb , 1996, The Lancet.

[88]  K. Mechtler,et al.  Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. , 1996, Human gene therapy.

[89]  E. Nabel,et al.  Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[90]  G. Gibbons,et al.  Molecular Therapies for Vascular Diseases , 1996, Science.

[91]  J. Wilson,et al.  Adenoviruses as gene-delivery vehicles. , 1996, The New England journal of medicine.

[92]  Peipei Ping,et al.  Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart , 1996, Nature Medicine.

[93]  J. Leiden,et al.  Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.

[94]  R. Evans,et al.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[95]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[96]  J. Leiden,et al.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. , 1995, The Journal of clinical investigation.

[97]  S. Epstein,et al.  Gene therapy for vascular disease , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[98]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[99]  G. Condorelli,et al.  Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo , 1995, Nature Medicine.

[100]  N. Yang,et al.  Gene gun and other non-viral approaches for cancer gene therapy , 1995, Nature Medicine.

[101]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[102]  J. Seltzer,et al.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.

[103]  S. Russell.  Replicating vectors for cancer therapy: a question of strategy. , 1994, Seminars in cancer biology.

[104]  Moolten Fl.  Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .

[105]  J. Burns,et al.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[106]  E. Nabel,et al.  Gene therapy for vascular smooth muscle cell proliferation after arterial injury. , 1994, Science.

[107]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[108]  S. Epstein,et al.  Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. , 1994, Circulation.

[109]  E. Brogi,et al.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.

[110]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[111]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[112]  H. T. Yang,et al.  Angiotensin-converting enzyme inhibition increases collateral-dependent muscle blood flow. , 1993, Journal of applied physiology.

[113]  G. Nabel,et al.  Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[114]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[115]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[116]  M. Colombo,et al.  Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. , 1992, Cancer research.

[117]  Michael Simons,et al.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo , 1992, Nature.

[118]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[119]  J. D. Watson.  The human genome project: past, present, and future. , 1990, Science.

[120]  R. Samulski,et al.  AAV vectors: is clinical success on the horizon? , 2000, Gene Therapy.

[121]  T. Clackson,et al.  Regulated gene expression systems , 2000, Gene Therapy.

[122]  Leaf Huang,et al.  Nonviral gene therapy: promises and challenges , 2000, Gene Therapy.

[123]  K. Yanagihara,et al.  Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells , 2000, Cancer Gene Therapy.

[124]  T. Hollon.  Researchers and regulators reflect on first gene therapy death , 2000, Nature Medicine.

[125]  F. Szoka,et al.  Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer–plasmid complexes , 1999, Gene Therapy.

[126]  Y. Kaneda.  Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. , 1999, Molecular membrane biology.

[127]  R. Crystal,et al.  Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. , 1998, The Journal of thoracic and cardiovascular surgery.

[128]  J. Isner.  Angiogenesis and Collateral Formation , 1997 .

[129]  Von der Leyen.  Gene therapy inhibiting neointimal vascular lesion , 1995 .

[130]  E. Nabel,et al.  Complex models for the study of gene function in cardiovascular biology. , 1994, Annual review of physiology.